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Abstract: Recent studies on diabetes and metabolic syndrome indicate a common disturbance of 
inorganic phosphate (Pi) metabolism. Pi is an important substrate in the formation of adenosine 
triphosphate (ATP), and many lifestyle diseases and cardiovascular risk factors similarly show 
deficiencies in either 1 or 2 major components of ATP synthesis. Age, male gender, hypertension, 
obesity, hypertriglyceridemia, metabolic syndrome, and diabetes mellitus are all associated 
with hypophosphatemia. In addition, tobacco smoking, hyperchylomicronemia, hypertension, 
and diabetes may involve defects in tissue oxygen delivery. Hypophosphatemia may lead to a 
critical decrease in intracellular Pi and to mitochondrial dysfunction, which might be counter-
acted by the pharmacological use of fructose 1,6-diphosphate.
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Introduction
Inorganic phosphate (Pi) is the ubiquitous anion required for intermediate metabolism 
and energy-transfer mechanisms. Pi is a vital component of DNA and RNA, and it 
is also present in phospholipids in membranes. Pi participates in both glycolysis and 
oxidative phosphorylation, the 2 major sources of adenosine triphosphate (ATP). 
In glycolysis, Pi is a substrate for glyceraldehyde-3-phosphate dehydrogenase and 
stimulates the activity of hexokinase and phosphofructokinase. In oxidative phos-
phorylation, Pi is a putative signaling molecule and takes part in the phosphorylation 
potential ATP/ADP × Pi. Bose et al1 have demonstrated in a multiparameter moni-
toring system applied to heart and skeletal muscle mitochondria that Pi controls the 
oxidative metabolism in a balanced fashion. Optimal amounts of both Pi and oxygen 
are required for a continuous supply of free energy according to the classical equation 
for oxidative metabolism:2 3ADP + 3Pi + 1/2O2 + NADH → 3ATP + NAD+ + H2O. 
If the production of ATP is interrupted or stopped for any reason, it may have serious 
consequences and may possibly lead to cell injury or cell death.
Plasma Pi is held within narrow limits through a complex interplay between 
intestinal absorption, exchange with intracellular and bone storage pools, and renal 
reabsorption. Intestinal absorption is mediated by sodium-phosphate cotransporter 
protein NaPi-IIb, which can be up-regulated and down-regulated when needed to 
maintain and exchange with intracellular and bone storage pools and renal reabsorption. 
The kidneys are the major regulators of Pi homeostasis, controlled by both hormonal 
and nonhormonal factors, and can increase and decrease Pi reabsorption capacity to 





Pi across the luminal membrane of the renal proximal tubules 
by the sodium phosphate-dependent cotransporter proteins 
that are bound to the brush border membrane, and the last 
intracellular loop of NaPi-IIa contains sequence information 
that confers parathyroid hormone (PTH) sensitivity.3 Because 
of the extensive literature, it is beyond the scope of this article 
to go further into details in the regulation of Pi homeostasis 
by PTH, vitamin D, phosphocalcins as fibroblast growth 
factor 23, phosphate regulating and Klotho genes, and more, 
but readers are referred to excellent reviews.4,5
Recently, we demonstrated a paradoxical metabolic 
imbalance in Pi from the early onset of diabetes, which may 
lead to a reduction in high energy phosphates and tissue 
hypoxia.6,7 This imbalance may be associated with the risk of 
late diabetic complications including cardiovascular disease. 
Hypophosphatemia, likewise, has been reported in studies 
of large numbers of individuals with metabolic syndrome.8,9 
As metabolic syndrome also has been shown to be closely 
associated with cardiovascular diseases,10,11 we were stimu-
lated to examine through Medline (PubMed), Embase, and 
reference lists whether other lifestyle diseases and risk factors 
may show similar biochemical alterations.
In this article, we will present evidence suggesting that 
many lifestyle diseases and risk factors are interrelated to 
deficiencies in 1 or 2 major components for optimal genera-
tion of ATP, eg, phosphate and/or oxygen.
Increasing age and male gender
More than 80% of deaths from coronary heart disease occur 
in patients of 65 years or older, an age at which female heart 
attack patients are more likely to die than men despite the 
fact that men have a greater risk of heart attack and suffer 
heart attacks earlier in life. Even after menopause, when 
women’s death rate from heart disease increases, it is not 
as great as men.12
The concentration of plasma Pi and the maximal renal 
tubular reabsorption of phosphate (TmPO4/GFR) are closely 
related to age and sex, with the highest values occurring in 
childhood. In adults, plasma Pi in men declines with age 
almost linearly, whereas in women under the age of 45, the 
values overlap those of men and then increase between 45 and 
54 years before declining thereafter. The practical implication 
is that phosphate-depleting disorders, such as diabetes and 
metabolic syndrome, might induce hypophosphatemia more 
easily in older persons because of the diminished tubular 
capacity for phosphate reabsorption before the development 
of such disorders.13
Diabetes mellitus
Cardiovascular diseases are the leading cause of diabetes-
related deaths. Substantial clinical and experimental evidence 
suggest that both diabetes and insulin resistance cause 
endothelial dysfunction, which may diminish the antiathero-
genic role of the vascular endothelium. In this respect, it is of 
interest that hypophosphatemia has been shown to increase 
insulin resistance and induce glucose intolerance.14–17 Hypo-
phosphatemia is a common finding in both type 1 and type 
2 diabetes, and several investigators have found decreased 
concentration of Pi in poorly regulated diabetic patients and 
slightly elevated levels when optimally controlled.6
Oxyhemoglobin dissociation is a measure of the ability 
of the red cells to release oxygen as they pass through the 
microcirculation. The position of the oxyhemoglobin disso-
ciation curve (ODC) is often expressed by the P50, (oxygen 
tension at 50% oxygen saturation). The position of the ODC 
is dependent of red cell 2, 3-diphosphoglycerate (2, 3-DPG) 
concentration. Oxygen release to tissues can be increased by 
interaction with a number of organic phosphates, primarily 2, 
3-DPG. In a variety of situations where tissue oxygenation is 
impaired, the 2, 3-DPG level rises, producing a proportional 
increase in P50 (a right shift of ODC). Such changes have 
been reported in anemia,18,19 cardiac failure,20,21 and cardio-
pulmonary insufficiency.22,23 Conversely, impaired synthesis 
of 2, 3-DPG is associated with a left shift of the ODC leading 
to a decreased delivery of oxygen to the venous end of the 
microvasculature (venous part of capillaries and venules).
In newly diagnosed, nonacidotic, type 1 diabetic patient’s 
plasma, the Pi concentration was normal at admission, lower 
on the day after initial insulin administration, and slightly 
above normal on the day when the best metabolic control is 
achieved. Red cell 2, 3-DPG exhibited the same fluctuating 
pattern, and Pi correlated closely with 2, 3-DPG (r = 0.61, 
P , 0.001). Red cell 2, 3-DPG correlated equally well with 
P50 of the ODC.24,25
To clarify the underlying mechanism leading to hypo-
phosphatemia, a study was performed in comparable groups 
of ambulatory, nonacidotic, insulin-dependent diabetic and 
healthy children. The average plasma Pi was significantly 
lower in the 26 children with diabetes compared with 
28 healthy children (1.36 vs 1.48 mmol/L, P , 0.005). In 
children with diabetes, the urinary phosphate excretion rate 
was significantly elevated (1.19 vs 0.43 mmol/h, P , 0.001), 
and phosphate excretion rate positively correlated with 
the urinary excretion rate of glucose (r = 0.53, P , 0.01) 
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threshold concentration of phosphate (TmPO4/GFR) was 
significantly suppressed in the children with diabetes (1.23 
vs 1.73 mmol/L, P , 0.001). This disturbance was related 
neither to changes in serum PTH nor to changes in growth 
hormone, but inversely correlated with the degree of hyper-
glycemia (r = 0.61, P , 0.001). The study demonstrates an 
abnormality in tubular phosphate reabsorption, which is 
related to glycemic regulation.26
However, in ambulatory subjects with juvenile diabetes 
with no evidence of vascular complications, despite an almost 
30% increase in the concentration of 2, 3-DPG at the same 
hemoglobin content, the P50 of the ODC was not increased.27 
This may be explained by the fact that hemoglobin A1c has 
increased the oxygen affinity and may react less readily with 
2, 3-DPG compared with regular hemoglobin A.28
Therefore, in patients with both type 1 and type 2 diabetes, 
there is a close correlation between the Pi concentration in 
plasma and improved diabetes control. In order for patients 
with diabetes to achieve optimal oxygen delivery to tis-
sues, the concentration of 2, 3-DPG and Pi must be higher 
than in healthy persons, partly because the red blood cells 
of patients with diabetes contain higher concentrations of 
hemoglobin A1c.
Obesity
Obesity is a major risk factor for cardiovascular diseases. 
Lindgärde and Trell29 found an inverse correlation between 
plasma Pi and body weight in 752 men born in 1926. Other 
parameters of minerals with possible relevance to their find-
ings were not found. In 194 subjects with a wide range of 
body mass index (BMI), Lind et al30 found that plasma Pi 
inversely correlated with BMI and fat distribution. PTH was 
not significantly correlated with any obesity parameters. 
Håglin et al8 conducted a large study of 1,272 women in 
whom serum phosphate inversely correlated with BMI.
Dyslipidemia
In apparently healthy persons, total cholesterol and low-
density lipoprotein cholesterol positively correlated with 
increasing Pi levels, and triglyceride concentration negatively 
correlated with plasma Pi levels.9
Hypertriglyceridemia and especially hyperchylomicrone-
mia have been found to interfere with tissue oxygen delivery. 
A marked left shift of the ODC has been demonstrated in 
familial type 1 hyperlipoproteinemia (familial combined 
hyperlipidemia), in diabetic and nondiabetic persons with 
hyperlipoproteinemia type V (mixed hypertriglyceridemia), 
and in blood mixed with lipid emulsions.31–33 The reason 
for this negative effect on tissue oxygen delivery might be 
an abolishment of the pH difference across the erythrocyte 
membrane resulting in a displacement of the ODC to the left 
by the Bohr effect.34
Tobacco smoking
Acute myocardial infarction or sudden death in patients 
with coronary artery disease is among the disorders strongly 
associated with cigarette smoking.35
Cigarette smoking is associated with increased levels of 
carboxyhemoglobin in the blood. This leads to a decrease in 
available hemoglobin for oxygen transport and will shift the 
ODC to the left, decreasing the volume of oxygen that can 
be unloaded to the tissue at any given Po2. Carbon monoxide 
also reduces the formation of 2, 3-DPG by inhibiting glyco-
lysis in the erythrocytes. The P50 of the ODC was decreased 
4 mmHg in a study of cigarette smoking.36,37 Smoking also 
releases the sympathetic neurotransmitter norepinephrine and 
the adrenomedullary hormone epinephrine and may thereby 
increase tissue oxygen demand.38 The oxygen availability or 
demand ratio will, therefore, decrease and the oxygen deficit 
may participate in adverse changes in the cardiovascular 
system.
Alcohol abuse
The metabolic effects of alcohol in man are complex since 
some are due to the direct action of ethanol or its metabolites, 
whereas some are related to the changes in the redox state 
or to nutritional factors.39 Hypophosphatemia and phos-
phate depletion are well recognized consequences of acute 
and chronic alcohol abuse.40 Hypophosphatemia has been 
suggested to cause myopathy, rhabdomyolysis, and cardio-
myopathy.41 Hypophosphatemia may be caused by a reduced 
renal threshold concentration of phosphate, but this might be 
only a part of a more complex tubular dysfunction.42,43 The 
presence of glycosuria and aminoaciduria with reduced renal 
threshold concentration of phosphate suggests a generalized 
reduction in the reabsorption ability of the proximal tubules. 
These data are supported by experimental studies indicating 
that ethanol interferes with the carrier function of the tubular 
cells by decreasing Na+/K+-ATPase activity.
Red cell 2, 3-DPG has been found to be increased, which 
has been suggested to be caused by a decrease in CO2 produc-
tion (cellular oxidation of alcohol produces 33% less CO2 
than cellular oxidation of glucose) leading to increased red 





to the Bohr effect.44 The similarities of alcohol intoxication 
and oxygen deprivation warrant further studies.
Hypertension
Ljunghall and Hedstrand45 conducted a population study 
of more than 2,000 men aged 49–50 years and showed 
that plasma Pi, within normal range, was inversely related 
to blood pressure. The presence of hypophosphatemia in 
hypertension has repeatedly been confirmed.46,47 Interestingly, 
a significant correlation was found between the rise in the 
initially low plasma Pi and the lowering of the initially high 
arterial blood pressure in overweight patients with essential 
hypertension.48
In spontaneous hypertensive rats, it was shown that the 
Pi and ATP in the vascular walls were reduced and that this 
reduced energy availability may contribute to a reduced 
response to vasoconstrictor agonists (noradrenaline and 
angiotensin II).49 Bindels et al50 in their study of hypertensive 
rats found that a disturbance in phosphate metabolism was 
already present at 6 weeks of age and that hypophosphatemia 
and hypophosphaturia were accompanied by an adaptive 
change in the transport capacity of Na+-dependent phosphate 
transport in brush border membranes from renal cortex. Older 
animals, at age 20 week, with marked hypophosphatemia 
showed reduced content of red cell 2, 3-DPG.
Epinephrine is a hypophosphatemic hormone in men,51 
and patients with hypertension have often been found to have 
increased plasma catecholamine concentrations consistent 
with the theory of a pathophysiologic role for increased 
sympathetic activity in this disease.52
Metabolic syndrome
There are different definitions of the metabolic syndrome. 
According to the Adult Treatment Panel III guidelines, 
metabolic syndrome is based on the presence of 3 or more 
of the following criteria: hypertension, impaired glucose 
tolerance, abdominal obesity, and dyslipidemia involving 
hypertriglyceridemia and decreased high-density lipoprotein 
cholesterol values.53
It was recently suggested that a disturbance in Pi metabo-
lism may be a basic and fundamental representative of this 
metabolic syndrome. Håglin54 studied 2,752 consecutive 
patients (1,190 men, 1,562 women) admitted during the 
years 1986–1996 to the patient education centre of Vindeln, 
a small community in northern Sweden. It was found that 
a low plasma Pi was associated with high BMI, high blood 
glucose, high systolic and diastolic blood pressures, but low 
serum high-density lipoprotein and serum magnesium levels. 
Another study by Kalaitzidis et al55 on 254 persons with a 
diagnosis of metabolic syndrome was based on Adult Treat-
ment Panel III guidelines. Subjects with fewer than 3 criteria 
served as controls. Patients with metabolic syndrome showed 
significantly lower plasma Pi and magnesium levels than 
controls. Because the fractional excretion of phosphate was 
similar in both groups, it was assumed that   hypophosphatemia 
in patients with metabolic syndrome was attributable to 
decreased dietary intake and internal redistribution of this 
element.
Discussion
Harden and Young56 in 1906 were the first to note that 
phosphorus played an important role in carbohydrate and 
energy metabolism, and the importance of phosphorus has 
been looming larger ever since. They furthermore found in 
living tissue a sugar-phosphate ester consisting of fructose 
with 2 phosphate groups, fructose diphosphate, also called 
Harden–Young ester.56 Pi is an important substrate for ATP 
formation both by oxidative phosphorylation and by glycoly-
sis. Because phosphate is a component of ATP, it also plays 
a pivotal role in the energy-related processes that take place 
in the endothelium and muscle cells of the cardiovascular 
system.57 Furthermore, without optimal oxygenation to the 
terminal electron acceptor in a reaction that is carried out 
by cytochrome c oxidase in the electron transport chain in 
mitochondria, the consequence of mitochondrial dysfunc-
tion may be endothelial dysfunction, increased endothelial 
permeability, or cell lyses.
Our study indicates that age, gender, hypertension, 
obesity, diabetes, hyperglyceridemia, and the metabolic 
syndrome all are associated with hypophosphatemia and 
increased risk for cardiovascular diseases. In addition, 
tobacco smoking, diabetes, and hyperchylomicronemia show 
defects in tissue oxygen delivery (Figure 1). In hypertension, 
microcirculation plays a critical role in that the increase in 
peripheral resistance underlying the raised blood pressure is 
localized to a narrowing of small arteries and precapillary 
arterioles with rarefaction of capillaries possibly leading to 
ischemic hypoxia. In diabetes, affinity hypoxia may be related 
to the increased levels of glycosylated hemoglobin, relative 
or absolute hypophosphatemia, and red cell 2, 3-DPG con-
tent. In diabetes mellitus, a major disturbance in phosphate 
handling occurs in the kidney tubules, where the excessive 
sodium-dependent glucose reabsorption in patients with 
diabetes depolarizes the electrochemical sodium gradient. 
Since Pi uses the same driving force but has less binding 
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alanine, the Pi reabsorption, particularly in poorly regulated 
patients, become impaired. Sodium-dependent phosphate 
transport has been described in many epithelial cells and 
may be a widespread process.58 It occurs in cells in which the 
entrance of glucose is not controlled by insulin and the result 
of hyperglycemia is increased sodium-dependent glucose 
transport. Besides the renal tubular cells, this may occur in 
the cardiovascular endothelium.59
In a double-blind study over 1 year to assess the effect of 
addition of 2 g of calcium diphosphate to the 3 main meals 
to 43 patients with juvenile diabetes, no increase was seen 
in the concentration of Pi (active = 19, 1.33 mmol/L vs pla-
cebo = 24, 1.42 mmol/L; P = ns). In the treatment group, the 
fasting urinary phosphate excretion significantly increased 
and the threshold concentration of Pi (TmPO4/GFR) was sup-
pressed. The threshold concentration was not related to the 
level of PTH or to growth hormone, but inversely correlated 
with the degree of hyperglycemia. Therefore, the normaliza-
tion of blood glucose levels leads to an improved capacity of 
the kidney tubules to reabsorb Pi and a subsequent increase 
in plasma Pi concentrations.6,60
The carbon monoxide, a byproduct of smoking, leads to a 
decrease in oxygen carrying capacity, a left shift (decreased 
P50) of the ODC, and a decrease in oxygen availability or 
demand ratio.
The large study by Park et al9 supports the findings of 
Håglin et al8 and that serum phosphate levels showed a 
negative correlation to age, BMI, fasting blood glucose, 
triglyceride levels, and systolic and diastolic blood pressures. 
However, it was also shown that it may be important to main-
tain an appropriate level of phosphate for the prevention of 
































Figure 1 The present concept indicates that the risk factors to cardiovascular disease lead to mitochondrial dysfunction due to either hypophosphatemia and/or hypoxia 





It is well established that patients and animals with very 
low plasma concentration of Pi have abnormal function of red 
blood cells, kidneys, brain, myocardium, pancreas, muscles, 
and nerves.61,62 The relationship between extracellular and 
intracellular availability of Pi is uncertain because the avail-
ability of Pi in various intracellular compartments is not well 
known. Freeman et al63 used nuclear magnetic resonance to 
provide an estimate of free Pi in intact renal cortex of rats. 
From their data, they calculated the intracellular concentra-
tion of free Pi to be 0.6 mmol/L. Brazy and Mandel64 used 
this estimate in combination with their own data relating 
phosphate dependence with oxidative phosphorylation in 
renal tubules and concluded that the availability of Pi in 
cortical renal tubules may be a factor in regulating rates of 
oxidative phosphorylation. They further showed that tran-
sepithelial phosphate transport provides Pi for use within cells 
and that intracellular metabolic processes compete for Pi. 
Perfusion of proximal convoluted tubules from rabbit kidney 
with phosphate-free medium containing glucose resulted in 
complete inhibition of the fluid absorption. It was suggested 
that as glycolysis increases, there is not enough intracellular 
phosphate for both glycolysis and mitochondrial respiration, 
and the rates of respiration decrease, thereby reducing the 
tissue content of ATP. Thus, these and other studies65,66 indi-
cate that pathways of intracellular metabolism may depend 
on and compete for intracellular phosphate.
Plasma Pi concentration appears to act as a double-edged 
sword. Several epidemiological studies have indicated that 
calcium, phosphate, and calcium–phosphate product may 
also be positively associated with increased risk of cardio-
vascular diseases.67,68 Interestingly, vitamin D levels that are 
directly correlated with plasma Pi have been found to be 
inversely related with the risk of cardiovascular diseases.69 
However, in end-stage renal failure, a U-shaped association 
of Pi and PTH to cardiovascular disease, with high risk in 
both hypophosphatemia and hyperphosphatemia, has been 
demonstrated.70,71 So, although we are dealing with complex 
processes, an explanation could be that hypophosphatemia 
leads to mitochondrial dysfunction and, in diabetes, to affinity 
hypoxia, whereas hyperphosphatemia promotes calcification 
of the vessel walls leading to ischemic hypoxia by narrowing 
or causing mechanical occlusion of both the macrovascula-
ture and the microvasculature.72–74
The negative effect of hypophosphatemia might be abro-
gated by increasing intracellular phosphate, which may be pos-
sible by using the key intermediate fructose 1,6-diphosphate 
(FDP). Natelson et al75 showed that orally administrated FDP 
as calcium salt was absorbed directly by the intestinal tract 
without splitting the phosphate linkage and that 6 g led to an 
increase of plasma Pi averaging 15%, citric acid 10.7%, and 
nonprotein organic phosphate, as much as, 173%. Further 
preclinical and clinical data indicate that FDP can enter cells 
and serve as a metabolizable substrate of glycolysis. FDP acts 
as human bioenergy. It can transport phosphorous intracel-
lularly and can deliver 4 mol of ATP per mole of FDP. FDP 
can be given orally and intravenously in humans and is well 
tolerated at pharmacological doses. Although FDP appears to 
be efficacious, no controlled study has been reported with this 
key intermediate in patients with cardiovascular risk factors.
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